AKYA vs. ATHA, PRLD, NAUT, HBIO, SEER, BNGO, PRE, RPID, AXDX, and OMIC
Should you be buying Akoya Biosciences stock or one of its competitors? The main competitors of Akoya Biosciences include Athira Pharma (ATHA), Prelude Therapeutics (PRLD), Nautilus Biotechnology (NAUT), Harvard Bioscience (HBIO), Seer (SEER), Bionano Genomics (BNGO), Prenetics Global (PRE), Rapid Micro Biosystems (RPID), Accelerate Diagnostics (AXDX), and Singular Genomics Systems (OMIC).
Athira Pharma (NASDAQ:ATHA) and Akoya Biosciences (NASDAQ:AKYA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.
In the previous week, Akoya Biosciences had 6 more articles in the media than Athira Pharma. MarketBeat recorded 6 mentions for Akoya Biosciences and 0 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 0.68 beat Akoya Biosciences' score of 0.00 indicating that Akoya Biosciences is being referred to more favorably in the news media.
Athira Pharma presently has a consensus target price of $19.00, indicating a potential upside of 645.10%. Akoya Biosciences has a consensus target price of $7.21, indicating a potential upside of 251.92%. Given Akoya Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Athira Pharma is more favorable than Akoya Biosciences.
Athira Pharma has a net margin of 0.00% compared to Athira Pharma's net margin of -72.68%. Akoya Biosciences' return on equity of -80.59% beat Athira Pharma's return on equity.
Athira Pharma has a beta of 2.91, indicating that its stock price is 191% more volatile than the S&P 500. Comparatively, Akoya Biosciences has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500.
57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 79.4% of Akoya Biosciences shares are held by institutional investors. 19.8% of Athira Pharma shares are held by company insiders. Comparatively, 7.3% of Akoya Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Akoya Biosciences has higher revenue and earnings than Athira Pharma. Akoya Biosciences is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.
Akoya Biosciences received 11 more outperform votes than Athira Pharma when rated by MarketBeat users. Likewise, 61.70% of users gave Akoya Biosciences an outperform vote while only 58.06% of users gave Athira Pharma an outperform vote.
Summary
Akoya Biosciences beats Athira Pharma on 10 of the 17 factors compared between the two stocks.
Get Akoya Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKYA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AKYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akoya Biosciences Competitors List
Related Companies and Tools
